Key result
Atorvastatin (10 μmol/L) significantly reduced enhanced platelet adhesion and von Willebrand factor release induced by cocaine and plasma from chronic cocaine consumers in vitro.
Why the study?
Does atorvastatin reduce the proadhesive and prothrombotic endothelial cell phenotype induced by cocaine and plasma from cocaine consumers in vitro?
Does atorvastatin reduce the proadhesive and prothrombotic endothelial cell phenotype induced by cocaine and plasma from cocaine consumers in vitro?
Atorvastatin mitigates cocaine-induced endothelial dysfunction in vitro by reducing platelet adhesion and improving NO production, suggesting a potential protective role against cocaine-associated vascular complications.
Hypothesis-generating for cocaine-related vascular protection; leaves open clinical translation in users.
OBJECTIVE: Cocaine consumption is a risk factor for vascular ischemic complications. Although endothelial dysfunction and accelerated atherosclerosis have been observed in cocaine consumers, the mechanisms underlying their pathogenesis are not fully understood. This study aimed at identifying the effects of atorvastatin in relation to a proadhesive and prothrombotic phenotype induced by cocaine and plasma from chronic cocaine users on endothelial cells. APPROACH AND RESULTS: Human umbilical vein endothelial cells were exposed to either cocaine or platelet-free plasma (PFP) from chronic cocaine consumers in the presence or absence of 10 μmol/L of atorvastatin. Atorvastatin significantly reduced the enhanced platelet adhesion that was induced by cocaine and PFP from chronic cocaine consumers, as well as the release of the von Willebrand factor. Atorvastatin also avoided striking alterations on cell monolayer structure triggered by both stimuli and enhanced NO reduction because of cocaine stimulation through disrupting interactions between endothelial nitric oxide synthase (eNOS) and caveolin-1, thus increasing eNOS bioavailability. Cocaine-increased tissue factor-dependent procoagulant activity and reactive oxygen species generation were not counteracted by atorvastatin. Although monocyte chemoattractant protein-1 levels were not significantly higher than controls either under cocaine or PFP stimulation, atorvastatin completely avoided monocyte chemoattractant protein-1 release in both conditions. Platelets stimulated with cocaine or PFP did not express P-selectin, glycoprotein IIb/IIIa, or CD40L and failed to adhere to resting human umbilical vein endothelial cell. CONCLUSIONS: Cocaine and patient plasma equally induced a proadhesive and prothrombotic phenotype in endothelial cells, except for von Willebrand Factor release, which was only induced by PFP from chronic cocaine consumers. Atorvastatin improved endothelial cell function by reducing cocaine-induced and PFP from chronic cocaine consumer-induced effects on platelet adhesion, cell architecture, and NO production.
No takes yet. Share an insight, caveat, or question.
Sáez et al. (2014) studied Cocaine consumption. Atorvastatin vs. Absence of atorvastatin was evaluated on Proadhesive and prothrombotic phenotype (platelet adhesion, von Willebrand factor release). Atorvastatin (10 μmol/L) significantly reduced enhanced platelet adhesion and von Willebrand factor release induced by cocaine and plasma from chronic cocaine consumers in vitro.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: